Skip to main content
Retour
Watch Compare

ZyVersa Therapeutics, Inc.

Qualité des données : 83%
ZVSA
OTC Manufacturing Chemicals
0,19 €
0,00 € (0,00%)
6 months return
—
Momentum
Neutral
Free cash flow
-5,11 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,08
Interest Coverage-49,67

Valorisation

PE (TTM)
-0,06
Au-dessus de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -5,11 M

Price History

Tendances Financières

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Surprises de Résultats

EPS
Reported Estimate
Q42023 Q12024 Q22024 Q32024
Reported -1 041,80 € -4,53 € -3,31 € -2,43 €
Estimate -21,40 € -3,70 € -3,75 € -1,60 €
Surprise -4768,22% -22,43% +11,73% -51,88%

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -24,95 M
ROE N/A ROA -241,30%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -5,11 M
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0,08
Debt / Equity N/A Current Ratio 0,08
Interest Coverage -49,67 Asset Turnover N/A
Working Capital -11,77 M Tangible Book Value -11,73 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,06 · EV/EBITDA: N/A
P/E Ratio -0,06 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -332,49%
Market Cap 1,54 M Enterprise Value 1,54 M

Per Share

EPS: -4,18 · FCF/Share: -0,63
EPS (Diluted TTM) -4,18 Revenue / Share N/A
FCF / Share -0,63 OCF / Share -0,63
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 20,50% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 20,50%
SBC-Adj. FCF -5,48 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023 FY2021
Revenue — — — — —
Net Income -24,95 M -9,41 M -75 018,0 -98,30 M -240 700,0
EPS (Diluted) -4,18 -8,48 — -108,97 —
Gross Profit — — — — —
Operating Income -25,49 M -9,14 M -820 068,0 -107,75 M -235 267,0
EBITDA — — — — —
R&D Expenses 1,11 M 1,78 M 399 894,0 3,21 M —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense -513 209,0 -269 856,0 — 457,0 —
Income Tax -851 659,0 6 745,0 -745 050,0 -9,46 M —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023 FY2021
Total Assets 347 901,0 20,60 M 118,51 M 22,11 M 77,14 M
Total Liabilities 12,73 M 12,08 M 18,51 M 11,04 M 3,65 M
Shareholders' Equity -12,39 M 8,52 M 99,66 M 11,07 M -2,26 M
Total Debt — — — — —
Cash & Equivalents — — — — 928 389,0
Current Assets 347 901,0 1,72 M 6,36 M 3,35 M 1,18 M
Current Liabilities 12,73 M 11,23 M 8,19 M 10,19 M 276 835,0

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,1 -1,5
P/B — 1,6
ROE % — -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3